Alpine Immune Sciences Stock Predictions

Healthcare > Biotechnology

Buy ALPN

*Your capital is at risk

$64.97

+0 (+0%)

At Close: Aug 19, 2024

Currently predicting for Thu, 25 Jun 2026

ALPN Live board

Community Bull/Bear

Target Next close

Join the ALPN prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

ALPN Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For ALPN

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

ALPN Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT ALPINE IMMUNE SCIENCES INC

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
NESR $25.06	0.439%	Jun 22
IDYA $28.98	25.19%	Jun 12
PHM $118.49	14.53%	Jun 10
DHI $146.71	13.50%	Jun 10
EAT $140.46	20.94%	Jun 05

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by